Absci (ABSI) Total Non-Current Liabilities (2020 - 2026)
Absci (ABSI) reported Total Non-Current Liabilities of $22.8 million for Q1 2026, down 28.62% on a YoY basis from $32.0 million in Q1 2025, and down 11.65% sequentially from $25.8 million in Q4 2025.
Absci (ABSI) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Absci (ABSI) has 7 years of Total Non-Current Liabilities data on file, last reported at $22.8 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities fell 28.62% year-over-year to $22.8 million; the trailing twelve-month figure through Mar 2026 stood at $22.8 million (down 28.62% YoY), and the FY2025 full-year result was $25.8 million, down 24.8% from the prior year.
- Total Non-Current Liabilities slipped to $22.8 million in Q1 2026, from $25.8 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $54.7 million in Q1 2022 to a low of $22.8 million in Q1 2026.
- A 5-year average of $37.9 million and a median of $35.0 million in 2025 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities tumbled 75.66% in 2022 and climbed 2.97% in 2025, its largest moves.
- Tracing ABSI's Total Non-Current Liabilities over 5 years: stood at $46.6 million in 2022, then retreated by 12.31% to $40.8 million in 2023, then slipped by 15.88% to $34.3 million in 2024, then declined by 24.8% to $25.8 million in 2025, then declined by 11.65% to $22.8 million in 2026.
- Business Quant data shows ABSI's Total Non-Current Liabilities at $22.8 million in Q1 2026, $25.8 million in Q4 2025, and $32.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Absci | 1.23 Bn | 1.11 Bn | - | 22.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22.82 Mn |
| Dec 31, 2025 | 25.83 Mn |
| Sep 30, 2025 | 32.87 Mn |
| Jun 30, 2025 | 35.04 Mn |
| Mar 31, 2025 | 31.97 Mn |
| Dec 31, 2024 | 34.34 Mn |
| Sep 30, 2024 | 33.87 Mn |
| Jun 30, 2024 | 34.03 Mn |
| Mar 31, 2024 | 34.71 Mn |
| Dec 31, 2023 | 40.83 Mn |
| Sep 30, 2023 | 39.93 Mn |
| Jun 30, 2023 | 38.75 Mn |
| Mar 31, 2023 | 41.84 Mn |
| Dec 31, 2022 | 46.56 Mn |
| Sep 30, 2022 | 46.41 Mn |
| Jun 30, 2022 | 49.90 Mn |
| Mar 31, 2022 | 54.74 Mn |
| Dec 31, 2021 | 47.93 Mn |
| Sep 30, 2021 | 48.98 Mn |
| Jun 30, 2021 | 204.96 Mn |